Project Grant R41AI096706

This Project Grant award, with a total funding amount of $146,922, was provided by the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855). The grant supports research to evaluate strategies for preventing Chlamydia trachomatis (CT) infections at the population level, including the use of prophylactic antibiotics and the development of a CT vaccine. Specifically, the project will: 1) Characterize the frequency and...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $226,204 to the University of Maryland, Baltimore to investigate the vaginal microbiome and immune response factors that contribute to the spontaneous clearance of Chlamydia trachomatis (CT) infections in women. The key objectives are to: (1) evaluate species- and strain-specific vaginal bacterial growth rates, (2)...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), aims to develop a bioadhesive vaginal film that provides extended release of contraceptive and antiviral monoclonal antibodies (mAbs). The $518,754 award to the Magee-Womens Research Institute and Foundation, with sub-awards to the University of Pittsburgh and Boston University, seeks to create a versatile,...

The National Institute of Allergy and Infectious Diseases (NIAID) awarded Sherlock Biosciences, Inc. a $429,244 Project Grant under the Allergy and Infectious Diseases Research program (CFDA 93.855) to develop a power-free, molecular diagnostic device for detecting Chlamydia trachomatis and Neisseria gonorrhoeae from self-collected vaginal swabs. The project aims to create an accurate, transportable, easy-to-use, and inexpensive screening solution that can be utilized by consumers in...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $300,000 in funding to Topaz Biosciences, Inc. to discover and optimize novel endolysins that can selectively target Gardnerella vaginalis, the primary bacterial species associated with bacterial vaginosis (BV). The goal is to develop improved endolysins that are more active, thermostable, and pH tolerant than...

This Project Grant award from the National Institute of Child Health and Human Development (NICHD), under the Child Health and Human Development Extramural Research program (CFDA 93.865), will support research to investigate the use of a selective TNFR2 blockade to prevent infertility associated with chlamydia pelvic inflammatory disease (PID). The $335,000 award, effective August 1, 2024 through July 31, 2026, will enable the establishment of a humanized TNFA/TNFR1/TNFR2 (HTNF) mouse model to...

This $1,670,110 Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID) under the Allergy and Infectious Diseases Research program (CFDA 93.855) supports the development of a novel, multi-compartment intravaginal ring (IVR) for the prevention of genital herpes (HSV) and unintended pregnancy. The key products and services funded under this award include: Evaluating a panel of small-molecule inhibitors of soluble adenylyl cyclase (SAC) to select a lead...

This Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), provides $299,999 to Planet Biotechnology Incorporated to develop a novel bispecific antibody for the prevention of gonorrhea. The project aims to engineer a fusion protein that combines elements of human antibodies with immune system components to broadly neutralize the causative bacteria, Neisseria gonorrhoeae, including...

This is a Project Grant award from the National Institute of Allergy and Infectious Diseases (NIAID), part of the Allergy and Infectious Diseases Research program (CFDA 93.855). The $207,225 award supports research to investigate how the bacterium Chlamydia trachomatis manipulates cellular pathways, specifically the PICALM protein, to maintain a "silent" infection within the host cell. The goal is to better understand how Chlamydia utilizes host cell nutrient trafficking to promote its...

This $1,025,000 project grant awarded by the National Institute of Allergy and Infectious Diseases (NIAID), under the Allergy and Infectious Diseases Research program (CFDA 93.855), is supporting the development of MM-009, a sustained-release intravaginal ring that continuously delivers lactic acid to prevent and treat bacterial vaginosis. The awardee, Mucommune LLC, a biopharmaceutical company in Durham, North Carolina, is focused on advancing this novel vaginal drug delivery technology. The...